MRSN · As filed with the SEC
Mersana Therapeutics balance sheet, by fiscal year
The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD thousands
| USD thousands | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 107,750 | 174,561 | 128,885 | 177,947 |
| Short-term marketable securities | 26,870 | 34,523 | 151,827 | — |
| Accounts receivable | — | 0 | 30,000 | — |
| Prepaid expenses and other current assets | 2,284 | 4,973 | 8,507 | 10,951 |
| Total current assets | 136,904 | 214,057 | 319,219 | 188,898 |
| Property and equipment, net | — | — | 3,985 | 1,968 |
| Property and equipment, net | 2,203 | 3,831 | — | — |
| Operating lease right-of-use assets | 4,578 | 7,694 | 10,475 | 12,889 |
| Other assets, noncurrent | 978 | 478 | 661 | 2,356 |
| Total assets | 144,663 | 226,060 | 334,340 | 206,111 |
| Liabilities and stockholders’ (deficit) equity | ||||
| Current liabilities: | ||||
| Accounts payable | 4,330 | 7,319 | 13,951 | 12,321 |
| Accrued expenses | 18,964 | 21,898 | 43,184 | 28,716 |
| Deferred revenue | 22,168 | 28,147 | 30,610 | 3,944 |
| Operating lease liabilities | 3,856 | 3,252 | 2,798 | 2,303 |
| Short-term debt | — | 2,083 | — | — |
| Short-term debt | 12,500 | — | — | — |
| Other current liabilities | 640 | 938 | 990 | 239 |
| Total current liabilities | 62,458 | 63,637 | 91,533 | 47,523 |
| Operating lease liabilities, noncurrent | 1,292 | 5,149 | 8,575 | 11,247 |
| Long-term debt, net | 10,950 | 23,148 | 24,929 | 24,626 |
| Deferred revenue, noncurrent | 79,464 | 97,167 | 117,043 | — |
| Other liabilities, noncurrent | 8 | 55 | 203 | 974 |
| Total liabilities | 154,172 | 189,156 | 242,283 | 84,370 |
| Stockholders' (deficit) equity | ||||
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 0 | 0 | 0 | 0 |
| Common stock, $0.0001 par value; 350,000,000 shares authorized; 115,649,928 and 120,711,745 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 12 | 12 | 11 | 7 |
| Additional paid-in capital | 886,022 | 863,242 | 746,889 | 572,213 |
| Accumulated other comprehensive income | 10 | 11 | (152) | — |
| Accumulated deficit | (895,553) | (826,361) | (654,691) | (450,479) |
| Total stockholders’ (deficit) equity | (9,509) | 36,904 | 92,057 | 121,741 |
| Total liabilities and stockholders’ (deficit) equity | 144,663 | 226,060 | 334,340 | 206,111 |
| Common stock, shares authorized (in shares) | — | 350,000,000 | 350,000,000 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.